scholarly journals SURGICAL MANAGEMENT AND BACTERIOLOGICAL OUTCOME OF INFRARENAL ABDOMINAL AORTIC GRAFT INFECTION AT A SINGLE CENTRE

Aim: Primary outcome measures was to analyze the clinical consequence of patients who treated for infrarenal aorta synthetic graft infection ( SGI) with extra-anatomical bypass (axillobifemoral (AXF)) or in situ reconstruction (ISR). Secondary outcome measure was to show bacteriological analysis of abdominal aorta graft infection. Method: Analysis of medical records of 24 patients treated for SGI at Jordanian Royal Medical Services between June 2010 and Aug 2020 were retrospectively reviewed. For all patients, we recorded clinical features , morbidity and mortality , as well as bacteriology results, and antibiotic treatment . Result: We identified 24(3%) patients with SGI .The median follow up duration was 22 months range (8-84months). The median age was 52 years and 18 were males. An in situ prosthetic graft replacement, using rifampin-soaked polyester graft was performed in 10 patients(42%) and AXF in 14 patients((58%). The early hospital mortality rate was 4 (17 %.) owing to bowel ischemia 1 patient, 2 patients with septicemia and one patient with aortic stump blowout . There were no late procedure-related deaths during follow up period Primary patency and limb salvage rates at 3 years were 80 %(2 patients ) for ISR and 90%( 2 patients) for AXF. The incidence of graft reinfection was 10% (1 patient) for ISR and 8 %(2 patients) for AXF. Graft reinfection occurred in 3 patients (12.5%) was not associated with procedure-related death .Microbiology specimens obtained from the graft and the tissues were positive in 21 patients(88%). Poly microbial Gram-positive organisms were the most dominant bacteria found in 10 patients (42%). The mean length of hospital stay was 17 days . Conclusion: According to our study ISR and AXF is a safe and effective in treatment of aortic graft infection. Graft reinfection occurred in 12.5% of the patients. The graft patency and limb salvages rates were considered satisfactory.

Vascular ◽  
2021 ◽  
pp. 170853812110253
Author(s):  
Thomas Betz ◽  
Markus Steinbauer ◽  
Ingolf Toepel ◽  
Christian Uhl

Objectives To report the midterm outcomes of treating prosthetic peripheral and aortic graft infections using a biosynthetic collagen prosthesis in a tertiary vascular center. Methods A retrospective analysis of all patients with prosthetic peripheral and aortic graft infections who underwent in situ reconstruction using a biosynthetic collagen prosthesis between March 2015 and November 2020 was conducted. Perioperative and midterm outcomes were analyzed. Results A biosynthetic collagen prosthesis was used in 19 patients (14 males, median age 66 years) to reconstruct the femoral artery ( n = 6), iliac artery ( n = 1), and infrarenal aorta ( n = 12). All patients were treated for a prosthetic vascular graft infection. The median follow-up period was 26.6 months (range 1–66 months). The 30-day graft failure rate was 15.7% ( n = 3), leading to a major amputation in one patient (5.3%). All grafts were occluded aortofemoral reconstructions in patients with occluded superficial femoral artery and were treated by immediate thrombectomy. The 30-day mortality rate was 5.3% ( n = 1), and survival after 3 years was 63.2%. The reinfection rate was 5.3% ( n = 1). At 13.6 months, the occlusion of a femoral graft was detected in 5.3% ( n = 1) and was treated with a new interposition graft. We observed no graft rupture or degeneration during follow-up. Conclusions Although results of in situ repair with autologous vein seem to be superior with little or none reinfection and low number of occlusions, biosynthetic collagen prostheses show acceptable midterm outcomes in terms of graft occlusion and mortality after prosthetic peripheral and aortic graft infections. Similar to other xenogenous materials, the reinfection rate is low with this prosthesis. With regard to immediate availability and easy handling, the use of a biosynthetic collagen prosthesis might be favorable compared to other replacement materials while treating prosthetic graft infections.


2013 ◽  
Vol 2013 (jul29 1) ◽  
pp. bcr2013010289-bcr2013010289 ◽  
Author(s):  
A. A. Karpenko ◽  
P. V. Ignatenko ◽  
A. M. Beliaev

Angiology ◽  
2017 ◽  
Vol 69 (5) ◽  
pp. 370-379 ◽  
Author(s):  
Michel Batt ◽  
Patrick Feugier ◽  
Fabrice Camou ◽  
Amandine Coffy ◽  
Eric Senneville ◽  
...  

2008 ◽  
Vol 48 (2) ◽  
pp. 503 ◽  
Author(s):  
M. Batt ◽  
E. Jean-Baptiste ◽  
S. O'Connor ◽  
P.-J. Bouillanne ◽  
P. Haudebourg ◽  
...  

2000 ◽  
Vol 48 (1) ◽  
pp. 43-44 ◽  
Author(s):  
H. Ogino ◽  
Y. Ueda ◽  
T. Sugita ◽  
K. Matsuyama ◽  
K. Matsubayashi ◽  
...  

Vascular ◽  
2012 ◽  
Vol 20 (3) ◽  
pp. 129-137 ◽  
Author(s):  
Michel Batt ◽  
Elixène Jean-Baptiste ◽  
Stephen O'Connor ◽  
Patrick Feugier ◽  
Stéphan Haulon

Management of aortic graft infection (AGI) remains contentious. The purpose of this study was to evaluate factors of clinical significance which influence the outcome of different treatment modalities for AGI. From 2000 to 2008, 82 consecutive patients were treated for AGI. In situ reconstruction (ISR) was performed in 63 patients with various conduits, extra-anatomic reconstruction (EAR) in 11, conservative treatment in five and resection without reconstruction in three. The perioperative mortality rate for the series (33%) was similar for EAR and ISR and was higher in patients with secondary aortoenteric fistula ( P < 0.001) in those undergoing emergency aortic reconstruction ( P < 0.001) and in AGI caused by virulent organisms ( P < 0.05). Fifteen (27%) of the surviving patients developed a recurrence of infection (RI). EAR patients were more exposed to RI ( P < 0.04). In conclusion, ISR may be more appropriate for AGI, but this study cannot draw a conclusion relating to the optimal conduit for ISR.


Sign in / Sign up

Export Citation Format

Share Document